Ozempic Gastroparesis Attorney: North Carolina Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Drug Safety

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy has empowered individuals to make informed decisions about their well-being, relying on accessible, evidence-based knowledge. Within this broad context, discussions around metabolic health and weight management have evolved significantly, introducing new pharmaceutical interventions that promise substantial benefits for chronic conditions such as type 2 diabetes and obesity. As these therapies become more widely adopted, a parallel focus has emerged on understanding their full spectrum of effects, including potential adverse outcomes that may arise during or after treatment. Specifically, attention has turned to the relationship between exposure to glucagon-like peptide-1 receptor agonists, such as Ozempic, and reports of gastrointestinal complications. Among these, gastroparesis—a condition characterized by delayed gastric emptying—has been identified as a serious concern for some patients.

Find Out If You Qualify for Compensation →

The Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes and, in higher doses, for chronic weight management. Its mechanism of action includes slowing gastric emptying, which contributes to its therapeutic effects on glycemic control and appetite reduction. However, this pharmacologic property also underlies a spectrum of gastrointestinal adverse effects, including a condition known as gastroparesis—a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent upper gastrointestinal symptoms and objective evidence of delayed gastric emptying, often via gastric emptying scintigraphy. The condition can significantly impair quality of life and lead to complications such as malnutrition, dehydration, and electrolyte imbalances. In the context of Ozempic use, the reported adverse events from the FDA Adverse Event Reporting System (FAERS) database include 2,693 reports of "impaired gastric emptying" (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). This figure places impaired gastric emptying among the most frequently reported adverse events for Ozempic, alongside nausea (8,652 reports), vomiting (5,578 reports), and diarrhea (5,274 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These data suggest a notable signal linking Ozempic to gastroparesis, though FAERS reports do not establish causation and may be subject to underreporting or confounding.

Pharmacologic Mechanism and Clinical Evidence

The mechanistic pathway linking Ozempic to gastroparesis is grounded in its pharmacology. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, an effect that is most pronounced during the initial weeks of treatment but can persist in some patients. The Ozempic prescribing information acknowledges that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo in clinical trials: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 34.0% with Ozempic 2 mg, compared to 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was also higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label lists dyspepsia, gastroesophageal reflux disease, and gastritis as less frequent reactions (each <5%), it does not explicitly mention gastroparesis as a distinct adverse reaction (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This omission raises questions about the adequacy of warnings regarding the risk of developing gastroparesis.

Legal Considerations for North Carolina Patients

From a risk perspective, the adequacy of warnings is a critical consideration for patients and healthcare providers. The prescribing information for Ozempic includes a boxed warning for thyroid C-cell tumors but does not contain a specific warning for gastroparesis. The gastrointestinal adverse reactions are described as occurring primarily during dose escalation, and the label advises that patients should be monitored for these symptoms. However, the absence of a dedicated warning for gastroparesis may leave patients unaware of the potential for a more severe and persistent form of delayed gastric emptying. For individuals who develop gastroparesis after starting Ozempic, the timeline between exposure and documented harm can vary. Some patients may experience symptoms within weeks of initiating therapy, while others may develop them after months of use. The FAERS data do not provide precise temporal information, but clinical reports suggest that symptoms can persist even after drug discontinuation in some cases. For affected patients in North Carolina, attorney-related considerations involve evaluating whether the manufacturer provided adequate warnings about the risk of gastroparesis. Legal claims may center on failure to warn, as the label does not explicitly list gastroparesis as a potential adverse effect despite the known pharmacologic mechanism and the substantial number of FAERS reports. Patients who have experienced severe gastrointestinal symptoms leading to hospitalization, nutritional deficiencies, or prolonged disability may seek compensation for medical expenses, lost wages, and pain and suffering. It is important for individuals to document their symptom onset, duration, and any medical diagnoses of gastroparesis, as well as to retain records of Ozempic prescriptions and healthcare provider communications. Consulting with a legal professional experienced in pharmaceutical litigation can help assess the viability of a claim based on the specific circumstances of exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it related to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Ozempic (semaglutide) works in part by slowing gastric emptying, which can cause or exacerbate gastroparesis. The FDA Adverse Event Reporting System has received thousands of reports of impaired gastric emptying associated with Ozempic (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).

Does the Ozempic label warn about gastroparesis?

The Ozempic prescribing information does not explicitly list gastroparesis as a potential adverse reaction, though it acknowledges gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea. The label notes that gastrointestinal events occurred more frequently with Ozempic than placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific warning for gastroparesis may be a basis for legal claims regarding failure to warn.

What legal options do North Carolina residents have if they developed gastroparesis after using Ozempic?

North Carolina residents who developed gastroparesis after using Ozempic may pursue legal claims based on inadequate warnings. An attorney experienced in pharmaceutical litigation can help evaluate whether the manufacturer failed to adequately warn about the risk of gastroparesis. Potential compensation may cover medical expenses, lost wages, and pain and suffering. It is important to document symptom onset, medical diagnoses, and prescription records.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.